Pregabalin for the treatment of generalized anxiety disorder: an update

References

• WittchenHUJacobiFRehmJThe size and burden of mental disorders and other disorders of the brain in Europe 2010Eur Neuropsychopharmacol201121965567921896369
   PubMed Web of Science ®Google Scholar
• WittchenHUJacobiFSize and burden of mental disorders in Europe – a critical review and appraisal of 27 studiesEur Neuropsychopharmacol200515435737615961293
   PubMed Web of Science ®Google Scholar
• LenzeEAnxiety disorders in the elderlySteinDHollanderERothbaumBTextbook of Anxiety Disorders2nd edWashingtonAmerican Psychiatric Publishing Inc2010651664
   Google Scholar
• BeesdoKKnappeSPineDSAnxiety and anxiety disorders in children and adolescents: developmental issues and implications for DSM-VPsychiat Clin N Am2009a323483524
   PubMed Web of Science ®Google Scholar
• AngstJGammaABaldwinDSAjdacic-GrossVRoesslerWThe generalized anxiety spectrum: prevalence, onset, course and outcomeEur Arch Psy Clin N200925913745
   Web of Science ®Google Scholar
• BruceSEYonkersKAOttoMWInfuence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective studyAm J Psychiat200516261179118715930067
   PubMed Web of Science ®Google Scholar
• WittchenHUKesslerRCBeesdoKKrausePHoflerMHoyerJGeneralized anxiety and depression in primary care: prevalence, recognition, and managementJ Clin Psychiat2002632434
   PubMed Web of Science ®Google Scholar
• KesslerRCDuPontRLBerglundPWittchenHUImpairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveysAm J Psychiat1999156121915192310588405
   PubMed Web of Science ®Google Scholar
• WittchenHUCarterRMPfisterHMontgomerySAKesslerRCDisabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national surveyInt Clin Psychopharm2000156319328
   PubMed Web of Science ®Google Scholar
• TyrerPSeivewrightHJohnsonTThe Nottingham Study of Neurotic Disorder: Predictors of 12-year outcome of dysthymic, panic and generalized anxiety disorderPsychol Med20043481385139415724870
   PubMed Web of Science ®Google Scholar
• BeesdoKHoyerJJacobiFLowNCPHoflerMWittchenHUAssociation between generalized anxiety levels and pain in a community sample: evidence for diagnostic specificityJ Anxiety Disord23568469319278819
   PubMed Web of Science ®Google Scholar
• AllgulanderCMorbid anxiety as a risk factor in patients with somatic diseases: a review of recent findingsMind Brain2010119
   Google Scholar
• MartensEJde JongePNaBCohenBELettHWhooleyMAScared to Death? Generalized Anxiety Disorder and Cardiovascular Events in Patients With Stable Coronary Heart Disease The Heart and Soul StudyArch Gen Psychiat201067775075820603456
   PubMed Web of Science ®Google Scholar
• SafrenSGershunyBMarzolPOttoMPollackMHistory of childhood abuse in panic disorder, social phobia, and generalized anxiety disorderJ Nerv Ment Dis2002190745345612142846
   PubMed Web of Science ®Google Scholar
• RosenbaumJBiedermanJBolduc-MurphyEBehavioral inhibition in childhood: a risk factor for anxiety disordersHarvard Rev Psychiat199311216
   PubMed Web of Science ®Google Scholar
• KendlerKSMajor depression and generalised anxiety disorder – Same genes, (partly) different environments – RevisitedBrit J Psychiat19961686875
   PubMed Web of Science ®Google Scholar
• HettemaJMPrescottCAKendlerKSGenetic and environmental sources of covariation between generalized anxiety disorder and neuroticismAm J Psychiat200416191581158715337647
   PubMed Web of Science ®Google Scholar
• MackintoshMAGatzMWetherellJLPedersenNLA twin study of lifetime generalized anxiety disorder (GAD) in older adults: genetic and environmental infuences shared by neuroticism and GADTwin Res Hum Genet200691303716611465
   PubMed Web of Science ®Google Scholar
• YouJSHuSYChenBLZhangHGSerotonin transporter and tryptophan hydroxylase gene polymorphisms in Chinese patients with generalized anxiety disorderPsychiatr Gen2005151711
   PubMed Web of Science ®Google Scholar
• DonnerJSipilaTRipattiSSupport for involvement of glutamate decarboxylase 1 and neuropeptide y in anxiety susceptibilityAm J Med Genet B2012159B3316327
   PubMed Web of Science ®Google Scholar
• UnschuldPIsingMSpechtMPolymorphisms in the GAD-2 gene-region are associated with susceptibility for unipolar depression and with a risk factor for anxiety disordersAm J Med Genet B2012150B811001109
   Web of Science ®Google Scholar
• VerburgKGriezEMeijerJPolsHDiscrimination between panic disorder and generalized anxiety disorder by 35% carbon dioxide challengeAm J Psychiat19951527108110837793449
   PubMed Web of Science ®Google Scholar
• CowleyDSDagerSRMcClellanJRoybyrnePPDunnerDLResponse to lactate infusion in generalized anxiety disorderBiol Psychiatry19882444094143408758
   PubMed Web of Science ®Google Scholar
• SeddonKEffects of 7.5% CO2 challenge in generalized anxiety disorderJ Psychopharmacol2011251435120233897
   PubMed Web of Science ®Google Scholar
• BaileyJEKendrickADiaperAPotokarJPNuttDJA validation of the 7.5% CO2 model of GAD using paroxetine and lorazepam in healthy volunteersJ Psychopharmacol200721424916533865
   PubMed Web of Science ®Google Scholar
• DiaperAOsman-HicksVRichAEvaluation of the effects of venlafaxine and pregabalin on the carbon dioxide inhalation models of Generalised Anxiety Disorder and panicJ Psychopharmacol20132713514522516666
   PubMed Web of Science ®Google Scholar
• BeckAEmeryGGreenbergRAnxiety Disorders and Phobias: a Cognitive PerspectiveNew YorkBasic Books1985
   Google Scholar
• BarlowDAnxiety and Its Disorders: the Nature and Treatment of Anxiety and PanicNew YorkGuilford1988
   Google Scholar
• BorkovecTAlcaineOBeharEAvoidance theory of worry and generalized anxiety disorderHeimbergRTurkCMenninDGeneralized Anxiety Disorder: advances in Research and ParcticeNew YorkGuilford200477108
   Google Scholar
• DugasMJMarchandALadouceurRFurther validation of a cognitive-behavioral model of generalized anxiety disorder: diagnostic and symptom specificityJ Anxiety Disord200519332934315686860
   PubMed Web of Science ®Google Scholar
• WellsAKingPMetacognitive therapy for generalized anxiety disorder: An open trialJ Behav Ther Exp Psy2006373206212
   Web of Science ®Google Scholar
• NitschkeJBSarinopoulosIOathesDJAnticipatory activation in the amygdala and anterior cingulate in generalized anxiety disorder and prediction of treatment responseAm J Psychiat2009166330231019122007
   PubMed Web of Science ®Google Scholar
• ColesMETurkCLHeimbergRGMemory bias for threat in generalized anxiety disorder: the potential importance of stimulus relevanceCognit Behav Ther2007362657317530492
   PubMedGoogle Scholar
• MacLeodCMathewsATataPAttentional bias in emotional disordersJ Abnorm Psychol198695115203700842
   PubMed Web of Science ®Google Scholar
• MathewsARichardsAEysenckMInterpretation of homophones related to threat in anxiety statesJ Abnorm Psychol198998312708637
   PubMed Web of Science ®Google Scholar
• MoggKBradleyBPMillarNWhiteJA follow-up study of cognitive bias in generalized anxiety disorderBehav Res Ther19953389279357487852
   PubMed Web of Science ®Google Scholar
• MoggKBaldwinDSBrodrickPBradleyBPEffect of short-term SSRI treatment on cognitive bias in generalised anxiety disorderPsychopharmacology (Berl)20041763–446647015549278
   PubMed Web of Science ®Google Scholar
• BaldwinDSWaldmanSAllgulanderCEvidence-based pharmacological treatment of generalized anxiety disorderInt J Neuropsychopharmacol2011a14569771021211105
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical ExcellenceGeneralised anxiety disorder and panic disorder (with or without agoraphobia) in adults: Management in primary, secondary and community care. NICE Clinical Guideline 113ManchesterNational Institute for Health and Clinical Excellence2011
   Google Scholar
• BaldwinDWoodsRLawsonRTaylorDEfficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysisBMJ2011b342d119921398351
   PubMed Web of Science ®Google Scholar
• MartinJLRSainz-PardoMFurukawaTAMartin-SanchezESeoaneTGalanCBenzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trialsJ Psychopharmacol200721777478217881433
   PubMed Web of Science ®Google Scholar
• ChessickCAAllenHAThaseMEAzapirones for generalized anxiety disorder [review]Cochrane Database of Systematic Reviews200619CD006115
   Google Scholar
• LalondeCDVan LieshoutRJTreating generalized anxiety disorder with second generation antipsychotics a systematic review and meta-analysisJ Clin Psychopharmacol201131332633321508847
   PubMed Web of Science ®Google Scholar
• GuaianaGBarbuiCCiprianiAHydroxyzine for generalised anxiety disorderCochrane Database of Syst Rev2010812CD00681521154375
   PubMed Web of Science ®Google Scholar
• MeibachRCDunnerDWilsonLGIshikiDDagerSRComparative efficacy of propranolol, chlordiazepoxide, and placebo in the treatment of anxiety: a double-blind trialJ Clin Psychiat1987489355358
   Web of Science ®Google Scholar
• BaldwinDSLoftHFloreaILu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorderInt Clin Psychopharm2012274197207
   PubMed Web of Science ®Google Scholar
• BaldwinDSAjelKThe role of pregabalin in the treatment of generalized anxiety disorderNeuropsychiatr Dis Treat20073218519119300552
   PubMedGoogle Scholar
• MicóJPrietoRElucidating the mechanism of action of pregabalin: α(2) δ as a therapeutic target in anxietyCNS Drugs201226863764822784017
   PubMed Web of Science ®Google Scholar
• BockbraderHNRadulovicLLPosvarELClinical pharmacokinetics of pregabalin in healthy volunteersJ Clin Pharmacol201050894195020147618
   PubMed Web of Science ®Google Scholar
• DaviesAKadurinIAlvarez-LaviadaAThe alpha(2)delta subunits of voltage-gated calcium channels form GPI-anchored proteins, a posttranslational modification essential for functionProc Natl Acad Sci USA201010741654165920080692
   PubMed Web of Science ®Google Scholar
• DaviesAHendrichJVan MinhATWrattenJDouglasLDolphinACFunctional biology of the alpha(2)delta subunits of voltage-gated calcium channelsTrends Pharmacol Sci200728522022817403543
   PubMed Web of Science ®Google Scholar
• LiZTaylorCPWeberMPregabalin is a potent and selective ligand for alpha(2)delta-1 and alpha(2)delta-2 calcium channel subunitsEur J Pharmacol20116671–3809021651903
   PubMed Web of Science ®Google Scholar
• BianFLiZOffordJCalcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an ex vivo autoradiographic study in alpha2-delta type 1 genetically modified miceBrain Res20061075688016460711
   PubMed Web of Science ®Google Scholar
• TaylorCPGarridoRImmunostaining of rat brain, spinal cord, sensory neurons and skeletal muscle for calcium channel alpha(2)-delta (alpha(2)-delta) type 1 proteinNeuroscience2008155251052118616987
   PubMed Web of Science ®Google Scholar
• AupperleRLRavindranLTankersleyDPregabalin influences insula and amygdala activation during anticipation of emotional imagesNeuropsychopharmacol201136714661477
   Web of Science ®Google Scholar
• WenselTMPoweKWCatesMEPregabalin for the treatment of generalized anxiety disorderAnn Pharmacother201246342442922395254
   PubMed Web of Science ®Google Scholar
• FeltnerDELiu-DumawMSchweizerEBielskiREfficacy of pregabalin in generalized social anxiety disorder: results of a doubleblind, placebo-controlled, fixed-dose studyInt Clin Psychopharm2011264213220
   PubMed Web of Science ®Google Scholar
• BelliottiTRCapirisTEkhatoIVStructure-activity relationships of pregabalin and analogues that target the alpha(2)-delta proteinJ Med Chem20054872294230715801823
   PubMed Web of Science ®Google Scholar
• LotarskiSMDonevanSEl-KattanAAnxiolytic-like activity of pregabalin in the vogel conflict test in alpha(2)delta-1 (R217A) and alpha(2)delta-2 (R279A) mouse mutantsJ Pharmacol Exp Ther2011338261562121558437
   PubMed Web of Science ®Google Scholar
• ErogluCAllenNJSusmanMWGabapentin receptor alpha 2 delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesisCell2009139238039219818485
   PubMed Web of Science ®Google Scholar
• FieldMJCoxPJStottEIdentification of the alpha(2)-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalinProc Natl Acad Sci USA200610346175371754217088553
   PubMed Web of Science ®Google Scholar
• PandeACCrockattJGFeltnerDEPregabalin in generalized anxiety disorder: a placebo-controlled trialAm J Psychiat2003160353354012611835
   PubMed Web of Science ®Google Scholar
• FeltnerDECrockattJGDubovskySJA randomized, doubleblind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorderJ Clin Psychopharmacol200323324024912826986
   PubMed Web of Science ®Google Scholar
• RickelsKPollackMHFeltnerDEPregabalin for treatment of generalized anxiety disorder – A 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolamArch Gen Psychiat20056291022103016143734
   PubMed Web of Science ®Google Scholar
• PohlRBFeltnerDEFieveRRPandeACEfficacy of pregabalin in the treatment of generalized anxiety disorder – Double-blind, placebo-controlled comparison of BID versus TID dosingJ Clin Psychopharmacol200525215115815738746
   PubMed Web of Science ®Google Scholar
• MontgomerySATobiasKZornbergGLKasperSPandeACEfficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxineJ Clin Psychiat2006675771782
   PubMed Web of Science ®Google Scholar
• PandeACrockattMJanneyCFeltnerDPregabalin treatment of GADAmerican Psychiatric Association 153rd Annual MeetingMay 13–18, 2006Chicago, IL, USA
   Google Scholar
• MontgomerySChatamraKPauerLWhalenEBaldinettiFEfficacy and safety of pregabalin in elderly people with generalised anxiety disorderBrit J Psychiat20081935389394
   Web of Science ®Google Scholar
• KasperSHermanBNivoliGEfficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a doubleblind, placebo-controlled 8-week trialInt Clin Psychopharm20092428796
   PubMed Web of Science ®Google Scholar
• FeltnerDWittchenH-UKavoussiRBrockJBaldinettiFPandeACLong-term efficacy of pregabalin in generalized anxiety disorderInt Clin Psychopharm20082311828
   PubMed Web of Science ®Google Scholar
• RickelsKShiovitzTMRameyTSWeaverJJKnappLEMiceliJJAdjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatmentInt Clin Psychopharm2012273142150
   PubMed Web of Science ®Google Scholar
• HidalgoRBTuplerLADavidsonJRTAn effect-size analysis of pharmacologic treatments for generalized anxiety disorderJ Psychopharmacol200721886487217984162
   PubMed Web of Science ®Google Scholar
• DonovanMRGluePKolluriSEmirBComparative efficacy of antidepressants in preventing relapse in anxiety disorders – A meta-analysisJ Affect Disord20101231–391619616306
   PubMed Web of Science ®Google Scholar
• Brawman-MintzerOKnappRGNietertPJAdjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled studyJ Clin Psychiat2005661013211325
   Web of Science ®Google Scholar
• PollackMHSimonNMZaltaAKOlanzapine augmentation of fuoxetine for refractory generalized anxiety disorder: a placebo controlled studyBiol Psychiatry200659321121516139813
   PubMed Web of Science ®Google Scholar
• AltamuraACSeratiMBuoliMDell’OssoBAugmentative quetiapine in partial/nonresponders with generalized anxiety disorder: a randomized, placebo-controlled studyInt Clin Psychopharm2011264201205
   PubMed Web of Science ®Google Scholar
• SimonNMConnorKMLeBeauRTQuetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findingsPsychopharmacology (Berl)2008197467568118246327
   PubMed Web of Science ®Google Scholar
• LohoffFWEtemadBMandosLAGallopRRickelsKZiprasidone treatment of refractory generalized anxiety disorder a placebo-controlled, double-blind studyJ Clin Psychopharmacol201030218518920520293
   PubMed Web of Science ®Google Scholar
• NuttDMandelFBaldinettiFEarly onset anxiolytic efficacy after a single dose of pregabalin: double-blind, placebo- and active-comparator controlled evaluation using a dental anxiety modelJ Psychopharmacol200923886787318635690
   PubMed Web of Science ®Google Scholar
• GonanoCLatzkeDSabeti-AschrafMKettnerSCChiariAGustorffBThe anxiolytic effect of pregabalin in outpatients undergoing minor orthopaedic surgeryJ Psychopharmacol201125224925319825903
   PubMed Web of Science ®Google Scholar
• PollackMHKornsteinSGSpannMECrits-ChristophPRaskinJRussellJMEarly improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpointJ Psychiatr Res200842141176118418348888
   PubMed Web of Science ®Google Scholar
• BaldwinDSSteinDJDolbergOTBandelowBHow long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial databaseHum Psychopharmacol200924426927519334042
   PubMed Web of Science ®Google Scholar
• BaldwinDSSchweizerEXuYLyndonGDoes early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?Eur Neuropsychopharmacol201222213714221839620
   PubMed Web of Science ®Google Scholar
• BechPDose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trialsPharmacopsychiatry200740416316817694480
   PubMed Web of Science ®Google Scholar
• HamiltonMThe assessment of anxiety states by ratingBr J Med Psychol1959321505513638508
   PubMed Web of Science ®Google Scholar
• LydiardRBRickelsKHermanBFeltnerDEComparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorderInt J Neuropsychopharmacol201013222924119737439
   PubMed Web of Science ®Google Scholar
• SteinDJBaldwinDSBaldinettiFMandelFEfficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studiesEur Neuropsychopharmacol200818642243018359203
   PubMed Web of Science ®Google Scholar
• MontgomerySAHermanBKSchweizerEMandelFSThe efficacy of pregabalin and benzodiazepines in generalized anxiety disorder presenting with high levels of insomniaInt Clin Psychopharm2009244214222
   Web of Science ®Google Scholar
• Holsboer-TrachslerEPrietoREffects of pregabalin on sleep in generalized anxiety disorderInt J Neuropsychopharmacol201225112
   Google Scholar
• PeggDBleavinsMHermanJHemangiosarcoma in mice administered pregabalin: analysis of genotoxicity, tumor incidence, and tumor geneticsToxicol Sci2012128192122539615
   PubMed Web of Science ®Google Scholar
• CriswellKAWojcinskiZPeggDKey components of the mode of action for hemangiosarcoma induction in pregabalin-treated mice: evidence of increased bicarbonate, dysregulated erythropoiesis, macrophage activation, and increased angiogenic growth factors in mice but not in ratsToxicol Sci20121281224122539625
   PubMed Web of Science ®Google Scholar
• CriswellKACookJCMorseDPregabalin induces hepatic hypoxia and increases endothelial cell proliferation in mice, a process inhibited by dietary vitamin E supplementationToxicol Sci20121281425622539613
   PubMed Web of Science ®Google Scholar
• CriswellKACookJCWojcinskiZMode of action associated with development of hemangiosarcoma in mice given pregabalin and assessment of human relevanceToxicol Sci20121281577122539620
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyLyrica (pregabalin)2013 Available from:www.emea.europa.eu/humandocs/Humans/EPAR/lyrica/lyrica.htmAccessed March 20, 2013
   Google Scholar
• ZaccaraGPeruccaPGangemiPFThe adverse event profile of pregabalin across different disorders: a meta-analysisEuropean Journal of Clinical Pharmacology201268690391222271298
   PubMed Web of Science ®Google Scholar
• OgawaSSatohJArakawaAYoshiyamaTSuzukiMPregabalin treatment for peripheral neuropathic pain: a review of safety data from randomized controlled trials conducted in Japan and in the westDrug Safety2012351079380622967187
   PubMed Web of Science ®Google Scholar
• TzellosTGToulisKAGoulisDGGabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysisJ Clin Pharm Ther201035663965621054455
   PubMed Web of Science ®Google Scholar
• WustmannTPiroJGutmannPMetabolic considerations in a case of pregabalin-induced edemaPharmacopsychiatry2009422757619308883
   PubMed Web of Science ®Google Scholar
• KruegerSLindstaedtMPregabalin and edema in young women suffering from premenstrual syndromePharmacopsychiatry201043520220320503153
   PubMed Web of Science ®Google Scholar
• GuzelkucukUDumanIYilmazBTanAKReversible post-pregabalin peripheral edema in a spinal cord injury patientSpinal Cord201250647247321747401
   PubMed Web of Science ®Google Scholar
• GallagherRApostleNPeripheral edema with pregabalinCMAJ [Epub November 5, 2012]
   Web of Science ®Google Scholar
• SendraJMJunyentTTPellicerMJRPregabalin-induced hepatotoxicityAnn Pharmacother2011456e32e3221652790
   PubMedGoogle Scholar
• ErdoganGCeyhanDGulecSPossible heart failure associated with pregabalin use: case reportAgri2011232808321644108
   PubMedGoogle Scholar
• AksakalEBakirciEMEmetMUzkeserMComplete atrioventricular block due to overdose of pregabalinAm J Emerg Med2012309
   Web of Science ®Google Scholar
• SjobergGFeychtingKPregabalin Overdose in Adults and Adolescents – Experience in SwedenClin Toxicol2010483282282
   Web of Science ®Google Scholar
• WoodDMBerryDJGloverGEastwoodJDarganPISignificant pregabalin toxicity managed with supportive care aloneJ Med Toxicol20106443543720373065
   PubMedGoogle Scholar
• KavoussiRPregabalin: from molecule to medicineEur Neuropsychopharmacol200616S128S13316765030
   PubMed Web of Science ®Google Scholar
• ZacnyJPPaiceJACoalsonDWSubjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteersPharmacol Biochem Behav2012100356056522085697
   PubMed Web of Science ®Google Scholar
• GrosshansMMutschlerJHermannDPregabalin abuse, dependence, and withdrawal: a case reportAm J Psychiat2010167786986920595436
   PubMed Web of Science ®Google Scholar
• FilipettoFAZippCPCorenJSPotential for pregabalin abuse or diversion after past drug-seeking behaviorJ Am Osteopath Assoc20101101060560721068226
   PubMedGoogle Scholar
• SchwanSSundstromAStjernbergEHallbergEHallbergPA signal for an abuse liability for pregabalin-results from the Swedish spontaneous adverse drug reaction reporting systemEur J Clin Pharmacol201066994795320563568
   PubMed Web of Science ®Google Scholar
• SchifanoFD’OffiziSPiccioneMIs there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam dataPsychother Psychosom201180211812221212719
   PubMed Web of Science ®Google Scholar
• GahrMFreudenmannRHiemkeCKölleMSchönfeldt-LecuonaCPregabalin abuse and dependence in Germany: results from a database queryEur J Clin Pharmacol20136961335134223292158
   PubMed Web of Science ®Google Scholar
• OulisPKonstantakopoulosGKouzoupisAVPregabalin in the discontinuation of long-term benzodiazepines’ useHum Psychopharmacol200823433734018348245
   PubMed Web of Science ®Google Scholar
• OulisPMasdrakisVGKarakatsanisNAPregabalin in the discontinuation of long-term benzodiazepine use: a case-seriesInt Clin Psychopharm2008232110112
   Web of Science ®Google Scholar
• OulisPNakkasGMasdrakisVGPregabalin in zolpidem dependence and withdrawalClin Neuropharmacol2011342909121407000
   PubMed Web of Science ®Google Scholar
• BobesJRubioGTeranAPregabalin for the discontinuation of long-term benzodiazepines use: an assessment of its effectiveness in daily clinical practiceEur Psychiatry201227430130721334859
   PubMed Web of Science ®Google Scholar
• HadleySJMandelFSSchweizerESwitching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trialJ Psychopharmacol201226446147021693549
   PubMed Web of Science ®Google Scholar
• StopponiSSomainiLCippitelliAPregabalin reduces alcohol drinking and relapse to alcohol seeking in the ratPsychopharmacology (Berl)20122201879621887495
   PubMed Web of Science ®Google Scholar
• BeckerHCMyrickHVeatchLMPregabalin is effective against behavioral and electrographic seizures during alcohol withdrawalAlcohol Alcohol200641439940616636010
   PubMed Web of Science ®Google Scholar
• GuglielmoRMartinottiGClericiMJaniriLPregabalin for alcohol dependence: a critical review of the literatureAdv Ther2012291194795723132700
   PubMed Web of Science ®Google Scholar
• BandelowBZoharJHollanderEWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revisionWorld J Biol Psychiatry20089424831218949648
   PubMed Web of Science ®Google Scholar
• BaldwinDSAllgulanderCBandelowBFerreFPallantiSAn international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorderWorld J Biol Psychiatry201213751051622059936
   PubMed Web of Science ®Google Scholar
• BandelowBSherLBuneviciusRWFSBP Task Force on Mental Disorders in Primary CareWFSBP Task Force on Anxiety Disorders, OCD and PTSDGuidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary careInt J Psychiatry Clin Pract2012162778422540422
   PubMed Web of Science ®Google Scholar